Esperion Therapeutics P/E Ratio

Esperion Therapeutics (ESPR) currently reports a P/E ratio of -131.4. That is below the Healthcare sector average of 26.85. Use the charts on this page to explore Esperion Therapeutics's P/E ratio history and peer comparisons.

Esperion Therapeutics's P/E ratio of -131.4 is lower than the Healthcare sector average of 26.85. That is roughly 589.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Esperion Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -131.4, ESPR can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -131.4, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Esperion Therapeutics, and consider following ESPR for alerts when major investors trade the stock.

Esperion Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -131.4 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ESPR with unrelated industries.